Dr. Françoise Pêne describes herself as a citizen of the world and indeed, her medical career is most certainly a reflection of that definition. On completing her medical studies, she became a hospital practitioner for over fifteen years, an intern in Paris hospitals followed by Assistant Chef then Chef de Clinique posts at the Institut Gustave Roussy and the Tenon-Saint-Antoine Faculty. Numerous specializations followed, often linked to inspirational scientific encounters. First, haematology, a field in which she became one of the rare French radiation experts before bone-marrow grafts (1995), followed by lymphomas and Hodgkin’s disease with doctors at the MD Anderson, Houston , Texas, USA, where she lived and worked for over a year under the auspices of Professor Lester Peters. She collaborated with the latter until she obtained her HDR (Habilitation à Diriger de Recherches) in Biological and Medical Sciences (1991). This renowned leader in the new technologies for the treatment of cancer across the Atlantic made the journey to France in order to be a member of her Habilitation jury.
An unprecedented event in the then life of the Pierre and Marie Curie University ! It caused a stir but established a tradition that has since been maintained on numerous occasions. Dr. Pêne then met Professor Emmanuel Van Der Schuren, from Louvain, an eminent European who sadly died prematurely in 1999. She worked with him for almost 10 years at the EORTC (a European group engaged in trials on all types of cancer) where she was given the honour of initiating and carrying out the very last post-operative trial on rectum cancers (1997) that emphasized the necessity of combining chemotherapy and radiotherapy, a procedure that has since become conformational. In 2001, Dr. Pêne became a member of the medical staff in the department of cancerology that consisted of both the radiotherapy department and Professor Lotz’s medical oncology department. Her research work concerned the optimization of radio-chemotherapy combinations in the treatment of digestive and head and neck cancers as well as primitive cerebral tumours. Since2003, Dr. Pêne has headed the uro-oncology unit at the Tenon Hospital where she has concentrated in particular on setting up the new technologies, with the evolution of radiotherapy from 3D to RCMl in prostate cancer (radiotherapy with modulation of intensity, making it possible to increase doses while protecting healthy tissue ).
Alongside her medical activities, Dr.Pêne, given her interest in the economics of the health service, studied at the ENA in order to gain a better understanding of how to implement these new technologies and new medication, called Targeted Therapeutics, in hospital departments with financial concerns. She has thus become able to exert a favourable influence on the installation of these new technologies and has twice been solicited as the expert advisor for the investments in the Assistance Publique Hospitals ( CT-scan – simulators in both the Henri Mondor and Pitié-Salpétrière Hospitals).
Dr. Pêne comes from a family of teachers and therefore has always attached considerable importance to the transmission of knowledge, both to young students at the DCEM 2 and 4 levels at the Pierre et Marie Curie Faculty and to those working towards a DIU in onco-geriatrics that is particularly renowned in France and French speaking countries. Indeed, since 2010, Dr. Pêne’s teaching and expertise activities are particularly in demand in Morocco both in oncology and onco-urology.
For the last two years, Dr. Pêne has also kept up a strong contact with her other adopted country, Senegal, where she collaborates with Professor Mamadiou Diop at the Dakar CHU ( University Teaching Hospital ), the Le Dantec Hospital. Their main concern is the training , in France, of doctors and para-medical technicians in the field of screening and treatment of female cancers.
For the last few years, Dr. Pêne, a fervent supporter of the Démocratie Sanitaire, has been giving conferences, organized by the ANAMACAP, that regroups patients and families affected by prostate cancer. Similarly, she has become a medical trainer and advisor to one of the most renowned institutes in France, the IFSI ( Institut de Formation pour les Soins Infirmiers ), the Louise Couvé Centre.
Finally, Dr. Pêne is one of the most influential members of the GETUG, (Groupe Français co-opérateur d’Etudes des Tumeurs Uro-Génitales) where most therapeutic protocols for prostate, bladder and kidney cancers are designed.
Dr. Pêne is the author of more than sixty internationally recorded articles that are accessible on the PUBMED site.
- Cost of prostate image-guided radiation therapy: results of a randomized trial.
Perrier L, Morelle M, Pommier P, Lagrange JL, Laplanche A, Dudouet P, Supiot S, Chauvet B, Nguyen TD, Crehange G, Beckendorf V, Pene F , Muracciole X, Bachaud JM, Le Prisé E, de Crevoisier R.
Radiother Oncol . 2013 Jan;106(1):50-8. doi: 10.1016/j.radonc.2012.11.011. Epub 2013 Jan 17
- [Dropped Head Syndrome after whiplash injury in a patient treated for a Hodgkin’s lymphoma by mantle field radiotherapy].
Schlienger M, Ferroir JP, Huguet F, Deluen F, Pène F , Marseguerra R, Touboul E.
Cancer Radiother . 2013 Feb;17(1):44-9. doi: 10.1016/j.canrad.2012.10.010. Epub 2012 Dec 4. Review. French
- [Fluoroethylthyrosine 18F PET in the detection of brain tumours].
Nataf V, Kerrou K, Balogova S, Pene F , Huchet V, Gutman F, Prignon A, Muresan IP, Giannesini C, Izrael V, Schlienger M, Talbot JN.
Bull Cancer . 2010 May;97(5):495-506. doi: 10.1684/bdc.2010.1078.
- [Hypofractionated stereotactic radiotherapy for brain metastases].
Schlienger M, Nataf F, Huguet F, Pene F , Foulquier JN, Orthuon A, Roux FX, Touboul E.
Cancer Radiother . 2010 Apr;14(2):119-27. doi: 10.1016/j.canrad.2009.10.004. Epub 2009 Dec 8. Review.
- [Epidermoid carcinomas of anal canal treated with radiation therapy and concomitant chemotherapy (5-fluorouracil and cisplatin).
Deniaud-Alexandre E, Touboul E, Tiret E, Sezeur A, Hannoun L, Houry S, Huguet F, Pène F , Parc R, Schlienger M.
Cancer Radiother . 2006 Dec;10(8):572-82. Epub 2006 Nov 15.
- [Anticancer drugs off label used of: what do the experts think about?.
Debrix I, André T, Becker A, Lotz JP, Gligorov J, Boukari Y, Milleron B, Pene F , Flahault A.
Bull Cancer . 2004 Oct; 91(10):769-77.
- Monitoring of residual hematopoiesis after total body irradiation in humans as a model for accidental x-ray exposure: dose-effect and failure of ex vivo expansion of residual stem cells in view of autografting.
Belkacémi Y, Bouchet S, Frick J, Huchet A , Pène F , Aigueperse J, Gourmelon P, Lopez M, Gorin NC.
Int J Radiat Oncol Biol Phys . 2003 Oct 1; 57(2):500-7
- Total-body irradiation before bone marrow transplantation for acute leukemia in first or second complete remission. Results and prognostic factors in 326 consecutive patients.
Belkacémi Y, Pène F , Touboul E, Rio B, Leblond V, Gorin NC, Laugier A, Gemici C, Housset M, Ozsahin M.
Strahlenther Onkol . 1998 Feb; 174(2):92-104
- Radical surgery and postoperative radiotherapy as combined treatment in rectal cancer. Final results of a phase III study of the European Organization for Research and Treatment of Cancer.
Arnaud JP, Nordlinger B, Bosset JF, Boes GH, Sahmoud T, Schlag PM, Pene F .
Br J Surg . 1997 Mar; 84(3):352-7
- Age is not a limiting factor for radical radiotherapy in pelvic malignancies.
Pignon T, Horiot JC, Bolla M, van Poppel H, Bartelink H, Roelofsen F, Pene F , Gerard A, Einhorn N, Nguyen TD, Vanglabbeke M, Scalliet P.
Radiother Oncol . 1997 Feb;42(2):107-20.